Cargando…

Expedited Development Programs at the Food and Drug Administration: Insights and Opportunities

Detalles Bibliográficos
Autores principales:	Collins, Grace, Stewart, Mark, Sigal, Ellen, Allen, Jeff
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021530/ https://www.ncbi.nlm.nih.gov/pubmed/33528806 http://dx.doi.org/10.1007/s43441-021-00258-z

Ejemplares similares

Opportunities to investigate the effects of ivermectin mass drug administration on scabies
por: Engelman, Daniel, et al.
Publicado: (2013)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs
por: Jenkins, Nola B, et al.
Publicado: (2023)

Expedited approval system for regenerative medicine products – Is it unusual?
por: Yano, Kazuo, et al.
Publicado: (2016)

New Food and Drug Administration Recommendations for Clozapine Prescribing and Monitoring Requirements
por: Mohapatra, Satyakam
Publicado: (2016)

The association between US Food and Drug Administration−expedited review designations and health plan specialty drug coverage
por: Panzer, Ari D, et al.
Publicado: (2023)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

Transesophageal Echocardiography Guidance for Expedited Pulmonary Artery Catheter Insertion and Accurate Estimation of Cardiac Output
por: Raut, Monish S, et al.
Publicado: (2018)

Experience of a resident physician in general surgery basic area on board of an expedition in the amazon river
por: MILANI, MARINA FANELLI LUCHIARI, et al.
Publicado: (2022)

COVID-19 and the food system: setback or opportunity for gender equality?
por: Ragasa, Catherine, et al.
Publicado: (2020)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Importance of Choice of Drugs and Timing of Their Administration
por: Yoo, Kyung Y., et al.
Publicado: (2012)

Costs and savings associated with a pharmacists prescribing for minor ailments program in Saskatchewan
por: Rafferty, Ellen, et al.
Publicado: (2018)

The Significance of Information Posted on the U.S. Food and Drug Administration’s Website
por: Cook, G. Elliott, et al.
Publicado: (2013)

Advancing precision oncology in metastatic colorectal cancer: The food and drug administration approval of foundation one liquid CDx as a companion diagnostic a correspondence
por: Shahnoor, Syeda, et al.
Publicado: (2023)

National Cancer Institute and Imaging—Intersecting Scientific Opportunity With Clinical Need
por: G. Feigal, Ellen, et al.
Publicado: (2004)

Insights and achievements from the Tara Pacific expedition
por: Planes, Serge, et al.
Publicado: (2023)

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
por: Kesselheim, Aaron S, et al.
Publicado: (2015)

Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
por: Putzke, Joerg, et al.
Publicado: (2021)

Comparability Considerations and Challenges for Expedited Development Programs for Biological Products
por: Schrieber, Sarah J., et al.
Publicado: (2020)

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
por: Kantor, Ariel, et al.
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Photocatalytic sequential C–H functionalization expediting acetoxymalonylation of imidazo heterocycles
por: Singh, Deepak, et al.
Publicado: (2023)

Safety Evaluation of an Expedited Omalizumab Home Self-Administration Pathway
por: Hussain, Zobia, et al.
Publicado: (2021)

Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system
por: Zhou, Yangzhong, et al.
Publicado: (2021)

Locally Acquired Leptospirosis in Expedition Racer, Manitoba, Canada
por: Kassim, Sameer S., et al.
Publicado: (2018)

Expedition
Publicado: (1959)

Missed opportunities in large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery
por: Krstajic, Damjan
Publicado: (2019)

Drug-micronutrient interactions: food for thought and thought for action
por: Karadima, Vasiliki, et al.
Publicado: (2016)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
por: Singh, Manish, et al.
Publicado: (2011)

Assessment of Public Opinion on Transparency at the US Food and Drug Administration
por: Azad, Tej D., et al.
Publicado: (2022)

Reply to “Missed opportunities in large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery”
por: Bosc, Nicolas, et al.
Publicado: (2019)

The need for a food allergy educator program for allied healthcare professionals in Canada
por: Protudjer, Jennifer L. P., et al.
Publicado: (2022)

The use of crisis line services during the COVID-19 pandemic: Evidence from the veterans health administration
por: Tenso, Kertu, et al.
Publicado: (2023)

Expedited drug review process: Fast, but flawed
por: Chary, Krishnan Vengadaraga
Publicado: (2016)

Drug choice for pediatric procedural sedation-analgesia and route of adrenaline administration in anaphylaxis treatment
por: Yeşilbaş, Osman, et al.
Publicado: (2019)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Senior residency: An opportunity missed?
por: Srivastava, Rajat M, et al.
Publicado: (2020)

Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
por: Ho, Cheryl, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rtm0gl6kv7hev74miq27getrav